Curenetics
Sola Adeleke has extensive work experience in the medical field. They began their career as an Oncology Registrar at The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust in 2012, and went on to work as an Oncology Registrar at Sheffield Teaching Hospitals NHS Foundation Trust and The Royal Marsden NHS Foundation Trust. In 2013, they joined Mid Essex Hospital NHS Trust as a Core Medical Trainee. Sola then worked as a Clinical Research Fellow at UCL, including a role at the NIHR Wellcome Trust UCL/UCLH Clinical Research Facility. In 2016, they became an NHS Clinical Entrepreneur Fellow at NHS England. In 2018, Sola founded their own company, Curenetics, where they served as the Chief Medical Officer (CMO). Most recently, Sola has taken on the role of an NIHR Academic Clinical Fellow in Clinical Oncology at King's College London since 2020.
Sola Adeleke has a Bachelor's degree in Medicine from Lagos State University, which was obtained from 2000 to 2007. Sola also holds a Master's degree in Business Administration from the University of Lagos, earned from 2003 to 2005. Additionally, they completed a Master of Science degree in Oncology and Cancer Biology from the University of Nottingham in 2010 and 2011. Sola Adeleke then pursued Core Medical Training at East of England Deanery from 2013 to 2015, obtaining the MRCP(UK) qualification. Recently, they completed their PhD in Cancer Magnetic Resonance Imaging in the field of Cancer functional imaging at UCL from 2016 to 2020.
This person is not in any teams
This person is not in any offices
Curenetics
1 followers
Curenetics is a fast-evolving and advancing start-up, working hard to defeat cancer using medical technology. Cancer treatment varies from patient to patient and many cancer types now require immune-oncologic treatment or other forms of targeted therapy. How a patient responds to their treatment regime is not fully known which can result in patients suffering from unwanted side effects or developing potentially life-threatening immune-mediated toxicities. We are currently working towards developing cancer treatment response models using artificial intelligence. We aim to predict response to immuno-oncologic treatments in cancer patients by leveraging our platform’s capability to find features within a large array of asynchronous clinical and genomic data. We are identifying biomarkers that will predict response to immunotherapy, even before starting treatment. At the same time, Curenetics is also building a flagship AI model to match cancer patients to the right clinical trial, whatever stage of treatment you are in. Through our machine learning-driven algorithms, domain expertise, and ability to combine cancer molecular profiling data, we are giving patients hope by helping to recruit them to the most suitable clinical trials available. At the same time, supporting trial sponsors to meet their recruitment targets, saving costs, and reducing time to trial completion.